ONTOLOGY REPORT - ANNOTATIONS |
|
Term: | N-acylethanolamine |
|
Accession: | CHEBI:52640
|
browse the term
|
Definition: | An ethanolamine substituted at nitrogen by an acyl group. |
Synonyms: | related_synonym: | Formula=C3H6NO2R; N-acylethanolamines; SMILES=OCCNC([*])=O; acylethanolamide; acylethanolamides |
| alt_id: | CHEBI:50870; CHEBI:52579 |
|
|
|
G |
App |
amyloid beta precursor protein |
|
11 |
24,425,013 |
24,641,872 |
RGD:6480464 |
G |
Bdkrb1 |
bradykinin receptor B1 |
|
6 |
129,437,423 |
129,441,553 |
RGD:6480464 |
G |
Cd36 |
CD36 molecule |
|
4 |
14,150,309 |
14,191,498 |
RGD:6480464 |
G |
Cnr1 |
cannabinoid receptor 1 |
|
5 |
49,307,584 |
49,333,064 |
RGD:6480464 |
G |
Cnr2 |
cannabinoid receptor 2 |
|
5 |
154,242,010 |
154,268,126 |
RGD:6480464 |
G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
7 |
70,578,564 |
70,585,074 |
RGD:6480464 |
G |
F3 |
coagulation factor III, tissue factor |
|
2 |
225,310,686 |
225,322,281 |
RGD:6480464 |
G |
Faah |
fatty acid amide hydrolase |
|
5 |
134,852,899 |
134,872,095 |
RGD:6480464 |
G |
Faahl |
fatty-acid amide hydrolase-like |
|
5 |
134,330,204 |
134,349,400 |
RGD:6480464 |
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
|
6 |
109,300,433 |
109,303,299 |
RGD:6480464 |
G |
Ifng |
interferon gamma |
|
7 |
61,337,383 |
61,341,419 |
RGD:6480464 |
G |
Igf1 |
insulin-like growth factor 1 |
|
7 |
28,412,123 |
28,491,815 |
RGD:6480464 |
G |
Il12b |
interleukin 12B |
|
10 |
30,034,447 |
30,048,774 |
RGD:6480464 |
G |
Il1b |
interleukin 1 beta |
|
3 |
121,876,256 |
121,882,637 |
RGD:6480464 |
G |
Lep |
leptin |
|
4 |
56,337,695 |
56,351,818 |
RGD:6480464 |
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
8 |
69,134,218 |
69,722,573 |
RGD:6480464 |
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
|
7 |
11,458,971 |
11,478,520 |
RGD:6480464 |
G |
Mapk1 |
mitogen activated protein kinase 1 |
|
11 |
88,203,863 |
88,273,301 |
RGD:6480464 |
G |
Mapk3 |
mitogen activated protein kinase 3 |
|
1 |
198,192,773 |
198,198,975 |
RGD:6480464 |
G |
Mmp1 |
matrix metallopeptidase 1 |
|
8 |
5,703,206 |
5,723,593 |
RGD:6480464 |
G |
Mmp3 |
matrix metallopeptidase 3 |
|
8 |
5,676,608 |
5,698,579 |
RGD:6480464 |
G |
Mmp9 |
matrix metallopeptidase 9 |
|
3 |
161,413,410 |
161,421,473 |
RGD:6480464 |
G |
Nos2 |
nitric oxide synthase 2 |
|
10 |
66,188,290 |
66,221,621 |
RGD:6480464 |
G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
7 |
126,618,872 |
126,687,282 |
RGD:6480464 |
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
13 |
67,351,230 |
67,356,920 |
RGD:6480464 |
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
X |
1,364,771 |
1,369,451 |
RGD:6480464 |
G |
Tnf |
tumor necrosis factor |
|
20 |
5,189,382 |
5,192,000 |
RGD:6480464 |
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
10 |
59,799,123 |
59,824,208 |
RGD:6480464 |
G |
Vegfa |
vascular endothelial growth factor A |
|
9 |
17,340,341 |
17,355,681 |
RGD:6480464 |
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
7 |
126,618,872 |
126,687,282 |
RGD:6480464 |
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
13 |
67,351,230 |
67,356,920 |
RGD:6480464 |
|
G |
Apob |
apolipoprotein B |
|
6 |
33,176,826 |
33,216,381 |
RGD:6480464 |
G |
Cnr1 |
cannabinoid receptor 1 |
|
5 |
49,307,584 |
49,333,064 |
RGD:6480464 |
G |
Cnr2 |
cannabinoid receptor 2 |
|
5 |
154,242,010 |
154,268,126 |
RGD:6480464 |
G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
9 |
27,366,404 |
27,381,004 |
RGD:6480464 |
G |
Lcn2 |
lipocalin 2 |
|
3 |
11,414,189 |
11,417,534 |
RGD:6480464 |
G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
7 |
126,618,872 |
126,687,282 |
RGD:6480464 |
Term paths to the root
Path 1 |
CHEBI ontology |
19654 |
 |
role |
19598 |
 |
application |
19220 |
 |
refrigerant |
16977 |
 |
ammonia |
16548 |
 |
organic amino compound |
16547 |
 |
amino alcohol |
862 |
 |
ethanolamines |
754 |
 |
N-acylethanolamine |
32 |
 |
(24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methyl-3-oxopentacosanamide |
0 |
 |
(26R)-26-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-3-oxoheptacosanamide |
0 |
 |
(2E,24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methylpentacos-2-enamide |
0 |
 |
1-[(Z)-alk-1-enyl]-sn-glycero-3-phospho-(N-acyl)ethanolamine + |
0 |
 |
11beta-prostaglandin F2alpha ethanolamide |
0 |
 |
N-(11Z,14Z)-eicosadienoylethanolamine |
0 |
 |
N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-5,8,11,14-tetraenamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-5,8,11-trienamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-8,11,14-trienamide |
0 |
 |
N-(2-hydroxyethyl)octadeca-9,12-dienamide |
0 |
 |
N-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-ethanolamine |
0 |
 |
N-(long-chain-acyl)ethanolamine + |
32 |
 |
N-(monounsaturated fatty acyl)ethanolamine + |
2 |
 |
N-(polyunsaturated fatty acyl)ethanolamine + |
29 |
 |
N-(saturated fatty acyl)ethanolamine + |
6 |
 |
N-acyl-sn-glycero-3-phosphoethanolamine + |
0 |
 |
N-acylethanolamine 16:0 |
0 |
 |
N-acylethanolamine 16:1 + |
0 |
 |
N-acylethanolamine 18:0 + |
0 |
 |
N-acylethanolamine 18:1 + |
2 |
 |
N-acylethanolamine 18:2 + |
0 |
 |
N-acylethanolamine 20:3 + |
0 |
 |
N-acylethanolamine 20:4 + |
29 |
 |
N-acylethanolamine 20:5 + |
0 |
 |
N-acylethanolamine 22:4 |
0 |
 |
N-acylethanolamine 22:5 |
0 |
 |
N-acylethanolamine 22:6 + |
0 |
 |
N-acyllysophosphatidylethanolamine + |
0 |
 |
N-gondoylethanolamine |
0 |
 |
prostaglandin D2 ethanolamide |
0 |
 |
prostaglandin F2alpha 1-ethanolamide |
0 |
 |
prostaglandin H2 1-ethanolamide |
0 |
 |
Path 2 |
CHEBI ontology |
19654 |
 |
subatomic particle |
19650 |
 |
composite particle |
19650 |
 |
hadron |
19650 |
 |
baryon |
19650 |
 |
nucleon |
19650 |
 |
atomic nucleus |
19650 |
 |
atom |
19650 |
 |
main group element atom |
19531 |
 |
main group molecular entity |
19531 |
 |
s-block molecular entity |
19314 |
 |
hydrogen molecular entity |
19303 |
 |
hydrides |
18231 |
 |
inorganic hydride |
17095 |
 |
pnictogen hydride |
17053 |
 |
nitrogen hydride |
16874 |
 |
azane |
16551 |
 |
ammonia |
16548 |
 |
organic amino compound |
16547 |
 |
amino alcohol |
862 |
 |
ethanolamines |
754 |
 |
ethanolamine |
55 |
 |
N-acylethanolamine |
32 |
 |
(24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methyl-3-oxopentacosanamide |
0 |
 |
(26R)-26-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-3-oxoheptacosanamide |
0 |
 |
(2E,24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methylpentacos-2-enamide |
0 |
 |
1-[(Z)-alk-1-enyl]-sn-glycero-3-phospho-(N-acyl)ethanolamine + |
0 |
 |
11beta-prostaglandin F2alpha ethanolamide |
0 |
 |
N-(11Z,14Z)-eicosadienoylethanolamine |
0 |
 |
N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-5,8,11,14-tetraenamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-5,8,11-trienamide |
0 |
 |
N-(2-hydroxyethyl)eicosa-8,11,14-trienamide |
0 |
 |
N-(2-hydroxyethyl)octadeca-9,12-dienamide |
0 |
 |
N-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-ethanolamine |
0 |
 |
N-(long-chain-acyl)ethanolamine + |
32 |
 |
N-(monounsaturated fatty acyl)ethanolamine + |
2 |
 |
N-(polyunsaturated fatty acyl)ethanolamine + |
29 |
 |
N-(saturated fatty acyl)ethanolamine + |
6 |
 |
N-acyl-sn-glycero-3-phosphoethanolamine + |
0 |
 |
N-acylethanolamine 16:0 |
0 |
 |
N-acylethanolamine 16:1 + |
0 |
 |
N-acylethanolamine 18:0 + |
0 |
 |
N-acylethanolamine 18:1 + |
2 |
 |
N-acylethanolamine 18:2 + |
0 |
 |
N-acylethanolamine 20:3 + |
0 |
 |
N-acylethanolamine 20:4 + |
29 |
 |
N-acylethanolamine 20:5 + |
0 |
 |
N-acylethanolamine 22:4 |
0 |
 |
N-acylethanolamine 22:5 |
0 |
 |
N-acylethanolamine 22:6 + |
0 |
 |
N-acyllysophosphatidylethanolamine + |
0 |
 |
N-gondoylethanolamine |
0 |
 |
prostaglandin D2 ethanolamide |
0 |
 |
prostaglandin F2alpha 1-ethanolamide |
0 |
 |
prostaglandin H2 1-ethanolamide |
0 |
 |
| |
|